This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?
Pharvaris N.V.(US:PHVS) The Motley Fool·2025-12-09 12:00A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.On November 14, Austin-based Saturn V Capital Management disclosed a new position in Pharvaris N.V. (PHVS), acquiring 886,332 shares valued at approximately $22.1 million during the third quarter.What HappenedAccording to a Securities and Exchange Commission (SEC) filing dated November 14, Saturn V Capital Management initiated a new position in Pharvaris N.V. (PHVS). The fund reporte ...